Literature DB >> 24981356

The malignant melanoma landscape.

Rachel M Webster1, Samuel E Mentzer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24981356     DOI： 10.1038/nrd4326

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  14 in total

1.  Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation.

Authors:  Xueqing Hu; Fangzhen Jiang; Qi Bao; Huan Qian; Quan Fang; Zheren Shao
Journal:  Tumour Biol       Date:  2015-08-14

2.  Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity.

Authors:  Stacy R Lindborg; Charles C Persinger; Andreas Sashegyi; Craig Mallinckrodt; Stephen J Ruberg
Journal:  Nat Rev Drug Discov       Date:  2014-08       Impact factor: 84.694

Review 3.  Regulatory considerations for clinical development of cancer vaccines.

Authors:  Bridget Theresa Heelan
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.

Authors:  Kristian M Koller; Heath B Mackley; Jason Liu; Henry Wagner; Giampaolo Talamo; Todd D Schell; Colette Pameijer; Rogerio I Neves; Bryan Anderson; Kathleen M Kokolus; Carol A Mallon; Joseph J Drabick
Journal:  Cancer Biol Ther       Date:  2016-12-01       Impact factor: 4.742

Review 5.  Adolescent and young adult patients with cancer: a milieu of unique features.

Authors:  Leonard Sender; Keri B Zabokrtsky
Journal:  Nat Rev Clin Oncol       Date:  2015-05-26       Impact factor: 66.675

6.  VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.

Authors:  Zheren Shao; Qi Bao; Fangzhen Jiang; Huan Qian; Quan Fang; Xueqing Hu
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

7.  Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells.

Authors:  Fangzhen Jiang; Kai Jin; Shenyu Huang; Qi Bao; Zheren Shao; Xueqing Hu; Juan Ye
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

8.  AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.

Authors:  Hilary M Sheppard; Vaughan Feisst; Jennifer Chen; Cris Print; P Rod Dunbar
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

Review 9.  Tailoring the Treatment of Melanoma: Implications for Personalized Medicine.

Authors:  Linna Duan; Eric M Mukherjee; Deepak Narayan
Journal:  Yale J Biol Med       Date:  2015-11-24

10.  Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma.

Authors:  Yongxia Zhu; Tinghong Ye; Xi Yu; Qian Lei; Fangfang Yang; Yong Xia; Xuejiao Song; Li Liu; Hongxia Deng; Tiantao Gao; Cuiting Peng; Weiqiong Zuo; Ying Xiong; Lidan Zhang; Ningyu Wang; Lifeng Zhao; Yongmei Xie; Luoting Yu; Yuquan Wei
Journal:  Sci Rep       Date:  2016-02-02       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.